The crux of chronic stress’s impact on cancer lies in its sustained activation of key neuroendocrine axes—most notably, the hypothalamic-pituitary-adrenal (HPA) axis and the sympathetic nervous system (SNS). Persistent stress triggers the continuous secretion of glucocorticoids, chiefly cortisol, alongside catecholamines such as norepinephrine and epinephrine. These stress mediators bind to specific receptors expressed on both malignant tumor cells and the myriad of stromal cells populating the tumor microenvironment. This receptor engagement remodels cellular behaviors, enhances malignancy, and impairs immunological defenses, creating a fertile ground for cancer progression.

Epidemiological data consistently demonstrate a robust association between chronic stress exposure and elevated cancer incidence as well as worsened mortality outcomes. Populations experiencing sustained stress due to financial instability, chronic pain, inflammation, or psychological distress exhibit disproportionately higher risks of tumorigenesis and metastatic spread. This contextualizes the clinical importance of dissecting the molecular and cellular circuitry by which stress hormones modulate tumor biology.

Crucially, chronic stress extends its influence beyond the malignant cells themselves, extensively remodeling the tumor microenvironment. Stress mediators are shown to suppress immune surveillance mechanisms—especially cytotoxic T lymphocyte activity—thereby undermining the body’s innate capacity to target and eradicate cancer cells. Concurrently, stress-induced angiogenic factors—such as vascular endothelial growth factor (VEGF)—promote the formation of new blood vessels, enhancing tumor perfusion and facilitating metastatic dissemination.

In specific cancer types, the impact of stress signaling demonstrates remarkable complexity. For instance, breast cancer cells exploit β-adrenergic receptor signaling to acquire stem-like traits, which not only drive tumor initiation but also confer resistance to chemotherapeutic agents. Pancreatic tumors subjected to stress-mediated inflammatory cues develop immune-excluded niches, effectively barricading cytotoxic immune cells from accessing malignant cells. Ovarian cancer progression is similarly accelerated, with stress pathways fostering early metastatic niche formation and colonization.

At the mechanistic level, multiple interconnected processes underpin the pro-tumorigenic effects of chronic stress. The activation of epithelial-mesenchymal transition (EMT) programs facilitates tumor invasiveness and dissemination. Stress also prompts the recruitment and polarization of immunosuppressive cells such as myeloid-derived suppressor cells and M2 macrophages, shifting the immune milieu towards one that favors tumor growth rather than elimination. This multifaceted signaling network culminates in an ecosystem that both sustains and propels cancer advancement.

The implications for clinical oncology are profound. Deciphering the intricate interplay within the psychoneuroimmune axis opens new horizons for intervention. Notably, preclinical models and emerging clinical trials have shown that pharmacological blockade of stress signaling — particularly through beta-adrenergic antagonists like propranolol — can decelerate tumor progression, enhance immune competence, and sensitize tumors to standard treatments. Complementary behavioral therapies, including exercise regimens and cognitive behavioral therapy, further modulate stress responses, presenting a holistic approach to integrative cancer care.

This reconceptualization of stress management transcends traditional supportive care paradigms, positioning psychosocial interventions as precision oncology tools capable of directly mitigating tumor-promoting pathways. By attenuating the deleterious effects of chronic neurological and hormonal stress responses, it may be possible to improve patient outcomes and extend survival across cancer subtypes.

Looking forward, the review highlights essential avenues for future research. Understanding the spatiotemporal dynamics of stress hormone release and signaling within the tumor microenvironment remains a critical challenge. Elucidating the complex crosstalk among diverse mediators and characterizing individual variability — shaped by genetics, sex differences, and cancer type — will refine therapeutic strategies. Moreover, interrogating the psychoneuroimmune networks underlying these interactions promises to reveal novel molecular targets and biomarkers to personalize anti-stress cancer therapies.

In summary, the comprehensive synthesis presented in Science Bulletin marks a paradigm shift in cancer biology, revealing chronic stress as a formidable architect of tumor progression. This work underscores the need to integrate neuroendocrine modulation into cancer treatment regimens, advocating for a multidisciplinary approach that encompasses both biological and psychosocial dimensions of patient care. Harnessing these insights may ultimately transform therapeutic landscapes and offer renewed hope against one of humanity’s most formidable diseases.

Subject of Research: Chronic Stress and Cancer Progression Mechanisms

Article Title: Chronic Stress-Induced Reprogramming of the Tumor Microenvironment Fuels Cancer Development and Metastasis

Web References:
DOI: 10.1016/j.scib.2025.09.034

Image Credits: ©Science China Press

Keywords: Life sciences, Health and medicine, Psychological stress, Chronic stress, Oncology, Signaling pathways

Exosomes function primarily as couriers within the TME, delivering proteins, nucleic acids, and metabolites that recalibrate the signaling networks among tumor and non-tumor cells. This vesicle-mediated dialogue profoundly impacts ferroptosis pathways, influencing whether cells succumb to or survive oxidative death. Ferroptosis, characterized by the overwhelming accumulation of lipid peroxides and reactive iron, has become recognized as a pivotal determinant in cancer cell fate and immune cell function. The ways in which exosomes modulate ferroptosis have implications that extend well beyond cell-intrinsic outcomes, contributing decisively to tumor metastasis.

Metastasis, the dissemination of malignant cells to distant organs, remains the principal cause of cancer-related mortality worldwide. Intriguingly, evidence underscores the role of exosomes in pre-conditioning remote tissues to form pre-metastatic niches—a preparatory landscape that supports cancer cell colonization. Exosomal cargoes from cancer and stromal cells within the TME enact a series of molecular events that promote vascular permeability, immune suppression, and metabolic rewiring, all of which facilitate metastatic seeding. Notably, exosomes derived from nasopharyngeal carcinoma (NPC) cells release macrophage migration inhibitory factor (MIF), which reprograms macrophage ferroptosis and encourages their polarization towards a pro-tumorigenic M2 phenotype. This dual role—protecting certain immune cells from death while fostering immunosuppressive behavior—illustrates the nuanced interplay at work.

Additionally, hepatocellular carcinoma (HCC)-derived exosomes delivering miR-142-3p highlight a distinct mechanism whereby ferroptosis is induced in M1 macrophages, dampening their antitumor activities and aiding tumor invasion. This immunosuppressive orchestration extends further as platelet-derived extracellular vesicles elevate integrin β3 expression in NPC cells, which suppresses SLC7A11, fostering ferroptosis resistance within tumor cells and enabling bloodstream-mediated metastasis. Collectively, these insights illustrate how exosome-mediated regulation of ferroptosis within immune and tumor cells orchestrates a permissive milieu for the metastatic cascade.

The immunosuppressive dimensions of ferroptosis regulation introduce another layer of complexity in tumor-immune system dynamics. Ferroptosis sustains a delicate balance, where protective mechanisms in immunosuppressive cell types such as M2 macrophages, Tregs, and tumor-infiltrating neutrophils hinge on glutathione peroxidase 4 (GPX4) activity to prevent lipid peroxidation. Disrupting these defenses through ferroptosis induction can eliminate suppressive immune cells, unleashing antitumor responses. Paradoxically, ferroptosis can also impair effector immune populations, including CD8+ T cells, natural killer cells, and dendritic cells, weakening the immune system’s ability to fight tumors. The dichotomous nature of ferroptosis in immunity reveals a complex regulatory network that cancer cells exploit to evade destruction.

Increasingly, exosomes have emerged as critical modulators at this immunological crossroads. For example, NPC- and colorectal cancer (CRC)-derived exosomes inhibit ferroptosis in macrophages, skewing polarization towards immunosuppressive states that favor tumor progression. Similarly, cancer-associated fibroblast (CAF)-derived exosomes can elevate the labile iron pool in natural killer (NK) cells, inducing ferroptosis and consequently diminishing their cytotoxic capacity against tumors. These vesicle-mediated ferroptosis interactions substantially contribute to the establishment of an immunosuppressive TME, underscoring exosomes as pivotal agents in cancer immune evasion.

Beyond modulating immune landscapes, exosomes wield significant influence over tumor drug resistance—a formidable barrier in cancer therapy. Traditional resistance mechanisms involve alterations in drug transporters, target mutations, and adaptive signaling changes. Yet, emerging research illuminates the roles of exosome-mediated ferroptosis pathways in counteracting therapy efficacy. Exosomal transfer of regulatory RNAs and proteins affects ferroptotic sensitivity in cancer cells, thereby shaping their response to chemotherapy and radiotherapy. This revelation invites reconsideration of therapeutic strategies that integrate ferroptosis modulation.

A prime example includes CAF-derived exosomal miR-522, which impedes ferroptosis in gastric cancer cells by downregulating arachidonic acid lipoxygenase 15 (ALOX15), diminishing lipid ROS accumulation. This cascade reduces sensitivity to paclitaxel and cisplatin, two cornerstone chemotherapeutics. Contrarily, the long noncoding RNA DACT3-AS1, also secreted by CAFs, has demonstrated ferroptosis-promoting effects via the miR-181a-5p/SIRT1 axis, enhancing oxaliplatin sensitivity. The interplay between ferroptosis inhibitors and promoters via exosomal transfer illustrates the complexity of chemoresistance phenotypes.

In pancreatic cancer, the development of gemcitabine resistance is similarly tied to exosomal signaling. CAF-secreted miR-3173-5p suppresses acyl-CoA synthetase long-chain family member 4 (ACSL4), a driver of ferroptosis, to bolster chemoresistance. Moreover, pancreatic cancer cell-derived exosomes containing medium-chain acyl-CoA dehydrogenase (ACADM) phenotypically correlate with gemcitabine sensitivity, linking fatty acid metabolism alterations to ferroptosis evasion. Therapeutically, silencing ACADM enhances gemcitabine efficacy, emphasizing the translational potential of targeting ferroptosis regulators within exosomal cargo.

Lung cancer models reveal further insights where exosomes from cisplatin-resistant cells are enriched in miR-4443, which suppresses ferroptosis regulator FSP1 via inhibition of m6A RNA modification pathways. This exosome-mediated epigenetic modulation fosters ferroptosis resistance, propagating acquired chemoresistance. Targeting this axis, either by inhibiting exosome secretion or miR-4443 function, offers promising avenues to overcome treatment failure.

Interestingly, adipocyte-derived exosomes also contribute to chemotherapy resistance, notably in colorectal cancer. These exosomes release the microprotein MTTP, influencing the PRAP1/ZEB1 axis to elevate GPX4 while reducing ACSL4 expression. This suppresses lipid ROS generation, dampens ferroptosis, and promotes oxaliplatin resistance. The feedback amplification triggered by chemotherapy-induced MTTP upregulation creates a reinforcing loop exacerbating drug resistance, further complicating treatment landscapes.

Radiotherapy resistance also emerges under the influence of exosomes. Hypoxic conditions characteristic of solid tumors induce lung cancer cells to secrete exosomes bearing high levels of ANGPTL4. This protein amplifies expression of key ferroptosis-regulatory proteins such as GPX4, SLC11A7, and FTH4, mitigating lipid peroxidation and iron-dependent cell death pathways. The result is enhanced radioprotection for tumor cells, underscoring the multifaceted roles of exosomes in therapeutic resistance beyond chemotherapy.

Collectively, this growing body of evidence situates exosome-mediated ferroptosis regulation as a central axis in cancer progression, immune suppression, metastasis, and treatment resistance. The intricate interplay between vesicle cargoes, iron metabolism, lipid peroxidation, and cellular phenotypes forms a sophisticated regulatory network that tumor cells exploit. Therapeutically targeting exosome biogenesis, release, or cargo content to modulate ferroptosis presents an innovative and promising frontier in overcoming the pervasive challenges of cancer treatment.

Future directions beckon integration of ferroptosis induction strategies with immunotherapy and conventional modalities, potentially unlocking synergistic effects. Additionally, monitoring exosomal markers of ferroptosis regulators may serve as liquid biopsy candidates, offering predictive insights into metastasis risk and drug responsiveness. As the field advances, a deeper mechanistic understanding of exosome-ferroptosis crosstalk in specific cancer types will be critical for designing precision medicine approaches.

In essence, the emerging paradigm positions exosomes not merely as passive carriers but as active architects of the tumor microenvironment, leveraging ferroptosis pathways to stymie immune defenses, foster metastatic spread, and blunt therapeutic efficacy. This conceptual shift invites a reassessment of cancer biology through the lens of intercellular vesicle exchange, heralding novel diagnostic and therapeutic breakthroughs.

Subject of Research:
Exosome-mediated regulation of ferroptosis within the tumor microenvironment and its impact on cancer progression, metastasis, immunosuppression, and drug resistance.

Article Title:
Exosome-mediated ferroptosis in the tumor microenvironment: from molecular mechanisms to clinical application.

Article References:
Liu, N., Wu, T., Han, G. et al. Exosome-mediated ferroptosis in the tumor microenvironment: from molecular mechanisms to clinical application. Cell Death Discov. 11, 221 (2025). https://doi.org/10.1038/s41420-025-02484-y

Image Credits:
AI Generated

DOI:
https://doi.org/10.1038/s41420-025-02484-y

Recent advancements in imaging technology have provided insights into the dynamics of how tumor-derived small extracellular vesicles are incorporated by target cells. This research was spearheaded by a team from Gifu University in Japan, led by Kenichi G. N. Suzuki. Their groundbreaking findings were published in the esteemed journal Nature Communications, shedding light on the intricate pathways through which these vesicles are internalized. The mechanism of uptake represents a pivotal area of study since a better comprehension of this process can lead to innovative approaches for cancer treatment and prevention.

Historically, researchers predominantly believed that the primary way cells internalized extracellular vesicles was through the fusion of the vesicle membrane and the recipient cell membrane. However, this new study challenges that notion by demonstrating that the process is primarily mediated through endocytosis rather than membrane fusion. Endocytosis is a cellular process where the target cell engulfs the extracellular vesicle, forming a vesicular compartment that houses the cargo. This understanding underscores the complexity of cellular interactions involved in the uptake of extracellular vesicles, particularly in the context of cancer biology.

Among the significant findings of this study is the identification of the proteins involved in the endocytosis of small extracellular vesicles. Contrary to common belief, the protein clathrin, typically associated with endocytic processes, did not facilitate the uptake observed in their experiments. Instead, the researchers discovered that the proteins galectin-3 and LAMP-2C were essential for the internalization of these cancer-derived extracellular vesicles. The presence of these proteins on the membrane of small extracellular vesicles raises intriguing questions about how tumor cells have adapted their vesicle-mediated communication strategies to alter the behavior of nearby healthy cells.

One of the key breakthroughs in the research was the ability to categorize tumor-derived extracellular vesicles into distinct subtypes. Using advanced imaging techniques, including single-molecule detection sensitivity, the scientists were able to monitor the distinct pathways of how different subtypes of vesicles interacted with target cells. This categorization is crucial, as it suggests that not all extracellular vesicles are created equal; their varying sizes, contents, and underlying mechanisms could significantly impact their functional properties and effectiveness as therapeutic agents.

The uptake mechanism elucidated by the team emphasizes the importance of calcium signaling during the process. It was observed that the binding of the extracellular vesicles to the recipient cells induced an increase in intracellular calcium concentrations. This increase appears to be a crucial factor enabling the cellular machinery to facilitate proper endocytosis of the vesicles. Such findings highlight the interplay between cellular receptors, signaling pathways, and vesicle dynamics, furthering the understanding of how cancer cells manipulate normal cellular processes to drive tumorigenesis and expansion.

An interesting aspect of paracrine signaling is its distinction from autocrine signaling. In paracrine adhesion signaling, molecules secreted by one cell influence nearby (usually different) cells, while in autocrine signaling, the effect is directed back at the originating cell. This fundamental difference implicates how cancer cells can create a supportive microenvironment for themselves while simultaneously evading the immune system and promoting their own survival.

The implications of this research are profound, as it opens new avenues for potential cancer therapies. By targeting the mechanisms involved in the uptake of extracellular vesicles, scientists aim to devise strategies to either inhibit the spread of cancer or use the vesicles themselves as delivery systems for therapeutic agents. The ability to modify the behavior of recipient cells presents exciting possibilities for creating more effective treatments that could impede cancer cell communication and reduce metastasis.

While the study represents a pivotal moment in understanding EVs’ role in cancer biology, it also poses numerous question for future research. Understanding the heterogeneity among different extracellular vesicle subtypes, their precise biochemical compositions, and how these influence their uptake and functionality will be vital to harnessing their potential in clinical applications. Furthermore, the role of the tumor microenvironment in modulating vesicle function and exploration of possible resistance mechanisms will be essential in developing effective cancer therapies.

As research continues to unravel the complexities of extracellular vesicle biology, scientists remain hopeful that these small messengers could be critical components in the arsenal against cancer. The findings from Gifu University serve as a foundational stone upon which the future of cancer diagnostics and therapeutics might be built, propelling ongoing investigations into how these vesicles can be manipulated for therapeutic gain.

In summary, the study conducted by Suzuki and colleagues has not only provided groundbreaking insights into how small extracellular vesicles derived from tumor cells are internalized by target cells but also paved the way for future research into their potential therapeutic uses. As understanding deepens, the integration of this knowledge into the clinical context could revolutionize the way we think about and treat cancer, ultimately improving outcomes for patients facing this challenging disease.

Subject of Research: Mechanisms of extracellular vesicle uptake in cancer cells
Article Title: Uptake of small extracellular vesicles by recipient cells is facilitated by paracrine adhesion signaling
News Publication Date: 12-Mar-2025
Web References: Nature Communications
References: Nature Communications, Kenichi G. N. Suzuki et al.
Image Credits: Kenichi Suzuki et al., Gifu University

Keywords: Extracellular vesicles, cancer biology, endocytosis, paracrine signaling, galectin-3, LAMP-2C, cellular communication, targeted therapy, tumor progression, imaging technology.